Evaluating drug targets through human loss-of-function genetic variation
Eric Vallabh Minikel(Broad Institute), Beryl B. Cummings(Rapt Therapeutics (United States)), Jessica Alföldi(Broad Institute), Richard C. Trembath(King's College London), Nicola Whiffin(Broad Institute), Daniel R. Rhodes(Howard Hughes Medical Institute), Hilary C. Martin(Wellcome Sanger Institute), Konrad J. Karczewski(Broad Institute), David A. van Heel(Queen Mary University of London), Mark J. Daly(Broad Institute)
Figshare
January 1, 2020
Cited by 163
Related Papers
PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
|Nature Genetics|2003|10.6k
Analysis of protein-coding genetic variation in 60,706 humans
|Nature|2016|10.3k
Biological insights from 108 schizophrenia-associated genetic loci
|Nature|2014|8.1k